←
COMy2,657 posts
COMy avatar

COMy

@COMyCongress

The World Congress on Controversies in Multiple Myeloma (COMy)

◷ Joined April 2016▧ 348 Photos and videos
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·15h

🎙️ What to Expect in Multiple Myeloma at #ASH26? Looking at the abstracts already available, one message is clear: 
we are witnessing a fundamental transformation in how we treat myeloma. We are moving beyond conventional combinations of: 
• Proteasome inhibitors 
• Immunomodulatory agents 
• Monoclonal antibodies Toward a landscape increasingly dominated by: 
• T-cell redirection 
• Multi-antigen targeting 
• Highly personalized immunotherapy The question is no longer just: 
How deep a response can we achieve? It is becoming: 
How do we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients' quality of life? In our new podcast, we highlight 5 major developments we believe deserve particular attention at #ASH26 in New Orleans. 🎧 Listen here: on.soundcloud.com/PR2CKPiJ8h… #MultipleMyeloma @Mohty_EBMT

Post attachment
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·Nov 12

🔴 We are Live! Making sense of treatment options at first relapse with Joseph Mikhael Join the webinar → @jmikhaelmd @Mohty_EBMT

0:20
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·Nov 11

🩺 CAR-T or bispecific? How do we approach early relapse? What comes after BCMA-directed therapy? Real-life decision making in the era of bispecifics! Join Mohamad Mohty and Douglas W. Sborov for interactive clinical cases, live polling & panel discussion. 📅 Dec 11 | New Orleans + Virtual 👉 Register: ash-symposium.iach.org/#regi… #MultipleMyeloma #IACH @Mohty_EBMT

Post attachment
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·Nov 8

🩺 What does the growing use of anti-BCMA bispecific mean for everyday clinical practice? Find out at the IACH Symposium at ASH 2026. This focused program will move beyond the clinical trial data to explore the questions that matter in practice — when to use bispecific, how to sequence them, how to manage toxicity and infections, and what to do when patients relapse after BCMA-directed therapy. 📅 December 11 | 07:00–10:00AM CT 💻 In person + virtual 👉 Register: ash-symposium.iach.org/#regi… This activity is approved for AMA PRA Category 1 𝘊𝘳𝘦𝘥𝘪𝘵™ #MultipleMyeloma #IACH #Hematology

Post attachment
Rahul Banerjee, MD, FACP avatar
⟳ COMy retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Nov 3

What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma? My best guess below... thanks @TheIACH @Mohty_EBMT for the invitation!

Post attachment
IACH@TheIACHNov 3

🔴 We are Live! CAR-T: Optimizing Bridging Therapy and Early Response with Rahul Banerjee Join the webinar → us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT

0:15
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·Oct 28

📣 Join IACH at ASH 2026! Explore the evolving role of anti-BCMA bispecific antibodies in multiple myeloma with an international expert faculty. From biology and clinical data to real-world implementation, toxicity management and interactive clinical cases. 📅 December 11 | 07:00–10:00AM CT 📍 In person + virtual 👉 Register now: ash-symposium.iach.org/#regi… This activity is approved for AMA PRA Category 1 CreditTM @Mohty_EBMT @NBahlis @mvmateos @ElenaZamagni #MultipleMyeloma #IACH

Post attachment
IACH avatar
⟳ COMy retweeted
IACH@TheIACH·Oct 28

Join us for the upcoming IACH Multiple Myeloma Masterclass Series: 𝗖𝗔𝗥-𝗧: 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗘𝗮𝗿𝗹𝘆 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 with Rahul Banerjee Tuesday, November 3 6 pm CET • 12 pm NY Register now for free👇 us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT

Post attachment